Which has better earnings and valuation, BHVN or PCVX?

Vaxcyte is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is BHVN or PCVX more profitable?

Vaxcyte's return on equity of -37.56% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Vaxcyte N/A -37.56% -33.62%

Does the media favor BHVN or PCVX?

In the previous week, Biohaven had 1 more articles in the media than Vaxcyte. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Biohaven's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BHVN or IBRX?

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A ImmunityBio $113.29M 79.33 -$351.40M -$0.97 N/A

Is BHVN or IBRX more profitable?

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% ImmunityBio -598.55% N/A -51.65%

Does the media refer more to BHVN or IBRX?

In the previous week, ImmunityBio had 2 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for ImmunityBio and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat ImmunityBio's score of 0.57 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, APGE or BHVN?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.34 N/A Biohaven N/A N/A -$738.82M -$4.64 N/A

Is APGE or BHVN more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Biohaven N/A -1,328.94% -138.27%

Which has preferable earnings & valuation, TGTX or BHVN?

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 14.12 $447.18M $2.74 20.76 Biohaven N/A N/A -$738.82M -$4.64 N/A

Is TGTX or BHVN more profitable?

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Biohaven N/A -1,328.94% -138.27%

Does the media favor TGTX or BHVN?

In the previous week, TG Therapeutics had 7 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for TG Therapeutics and 4 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.86 beat Biohaven's score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, IMVT or BHVN?

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Biohaven N/A N/A -$738.82M -$4.64 N/A

Is IMVT or BHVN more profitable?

Immunovant's return on equity of -69.59% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Biohaven N/A -1,328.94% -138.27%

Does the media favor IMVT or BHVN?

In the previous week, Biohaven had 1 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Immunovant. Immunovant's average media sentiment score of 0.60 beat Biohaven's score of 0.58 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biohaven (BHVN) Competitors

$13.58 -0.31 (-2.26%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$13.40 -0.17 (-1.26%)

As of 09/18/2026 07:30 PM Eastern

Compare

BHVN vs. PCVX, IBRX, APGE, TGTX, and IMVT

Should you buy Biohaven stock or one of its competitors? Biohaven's main competitors and comparable companies include Vaxcyte (PCVX), ImmunityBio (IBRX), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biohaven compare to Vaxcyte?

Biohaven (NYSE:BHVN) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biohaven currently has a consensus price target of $18.69, suggesting a potential upside of 37.65%. Vaxcyte has a consensus price target of $98.00, suggesting a potential upside of 68.59%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Biohaven had 1 more articles in the media than Vaxcyte. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Biohaven's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Vaxcyte's return on equity of -37.56% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Vaxcyte	N/A	-37.56%	-33.62%

Summary

Biohaven beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Biohaven compare to ImmunityBio?

Biohaven (NYSE:BHVN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, ImmunityBio had 2 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for ImmunityBio and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat ImmunityBio's score of 0.57 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Biohaven currently has a consensus target price of $18.69, suggesting a potential upside of 37.65%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 67.45%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Biohaven has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
ImmunityBio	-598.55%	N/A	-51.65%

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
ImmunityBio	$113.29M	79.33	-$351.40M	-$0.97	N/A

Summary

ImmunityBio beats Biohaven on 9 of the 16 factors compared between the two stocks.

How does Biohaven compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Biohaven had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 4 mentions for Biohaven and 0 mentions for Apogee Therapeutics. Biohaven's average media sentiment score of 0.58 beat Apogee Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Biohaven	Positive

Apogee Therapeutics presently has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Biohaven has a consensus target price of $18.69, suggesting a potential upside of 37.65%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

Apogee Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Apogee Therapeutics' return on equity of -29.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Biohaven	N/A	-1,328.94%	-138.27%

Summary

Biohaven beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Biohaven compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 10.78%. Biohaven has a consensus target price of $18.69, suggesting a potential upside of 37.65%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

In the previous week, TG Therapeutics had 7 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for TG Therapeutics and 4 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.86 beat Biohaven's score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Biohaven	N/A	-1,328.94%	-138.27%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	14.12	$447.18M	$2.74	20.76
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Summary

TG Therapeutics beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

In the previous week, Biohaven had 1 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Immunovant. Immunovant's average media sentiment score of 0.60 beat Biohaven's score of 0.58 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Immunovant has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 19.08%. Biohaven has a consensus price target of $18.69, indicating a potential upside of 37.65%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

Immunovant's return on equity of -69.59% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Biohaven	N/A	-1,328.94%	-138.27%

Summary

Biohaven beats Immunovant on 9 of the 14 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.06B	$3.90B	$7.24B	$23.10B
Dividend Yield	N/A	3.64%	2.57%	3.62%
P/E Ratio	-2.93	14.23	275.49	28.21
Price / Sales	N/A	1,419.61	646.01	20.34
Price / Cash	N/A	108.90	76.25	36.36
Price / Book	34.81	15.45	10.46	4.67
Net Income	-$738.82M	-$22.86M	$3.49B	$1.07B
7 Day Performance	6.43%	-1.21%	0.59%	-1.64%
1 Month Performance	0.04%	-3.29%	-1.74%	-3.60%
1 Year Performance	-5.33%	37.74%	18.13%	8.41%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.9295 of 5 stars	$13.58 -2.3%	$18.69 +37.7%	-5.3%	$2.06B	N/A	N/A	274	Positive News Analyst Forecast
PCVX Vaxcyte	2.1208 of 5 stars	$58.90 -1.0%	$86.00 +46.0%	+83.1%	$8.86B	N/A	N/A	507	Positive News
IBRX ImmunityBio	2.1897 of 5 stars	$7.72 -4.2%	$14.20 +83.9%	+210.6%	$8.54B	$113.29M	N/A	691
APGE Apogee Therapeutics	1.048 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91
TGTX TG Therapeutics	3.3736 of 5 stars	$55.39 +1.4%	$63.00 +13.7%	+75.7%	$8.37B	$616.29M	20.22	399

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. PCVX, IBRX, APGE, TGTX, and IMVT

How does Biohaven compare to Vaxcyte?

Summary

How does Biohaven compare to ImmunityBio?

Summary

How does Biohaven compare to Apogee Therapeutics?

Summary

How does Biohaven compare to TG Therapeutics?

Summary

How does Biohaven compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. PCVX, IBRX, APGE, TGTX, and IMVT

How does Biohaven compare to Vaxcyte?

Which has more risk & volatility, BHVN or PCVX?

Do insiders & institutionals have more ownership in BHVN or PCVX?

Do analysts rate BHVN or PCVX?

Does the media favor BHVN or PCVX?

Which has better earnings and valuation, BHVN or PCVX?

Is BHVN or PCVX more profitable?

Summary

How does Biohaven compare to ImmunityBio?

Does the media refer more to BHVN or IBRX?

Do analysts recommend BHVN or IBRX?

Which has more risk and volatility, BHVN or IBRX?

Is BHVN or IBRX more profitable?

Do institutionals & insiders hold more shares of BHVN or IBRX?

Which has better earnings and valuation, BHVN or IBRX?

Summary

How does Biohaven compare to Apogee Therapeutics?

Do insiders and institutionals hold more shares of APGE or BHVN?

Does the media favor APGE or BHVN?

Do analysts prefer APGE or BHVN?

Which has more risk & volatility, APGE or BHVN?

Which has better earnings and valuation, APGE or BHVN?

Is APGE or BHVN more profitable?

Summary

How does Biohaven compare to TG Therapeutics?

Do analysts rate TGTX or BHVN?

Does the media favor TGTX or BHVN?

Which has more risk and volatility, TGTX or BHVN?

Is TGTX or BHVN more profitable?

Do institutionals and insiders hold more shares of TGTX or BHVN?

Which has preferable earnings & valuation, TGTX or BHVN?

Summary

How does Biohaven compare to Immunovant?

Does the media favor IMVT or BHVN?

Do institutionals & insiders believe in IMVT or BHVN?

Which has higher valuation & earnings, IMVT or BHVN?

Which has more risk & volatility, IMVT or BHVN?

Do analysts prefer IMVT or BHVN?

Is IMVT or BHVN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools